Overview
flowchart TD
companies_ad_epigenetic_reader["Alzheimers Disease Epigenetic Reader and BET Br"]
style companies_ad_epigenetic_reader fill:#4fc3f7,stroke:#333,color:#000
companies_ad_epigene_0["Key Therapeutic Approaches"]
companies_ad_epigenetic_reader -->|"includes"| companies_ad_epigene_0
style companies_ad_epigene_0 fill:#81c784,stroke:#333,color:#000
companies_ad_epigene_1["BET Bromodomain Inhibitor Companies"]
companies_ad_epigenetic_reader -->|"includes"| companies_ad_epigene_1
style companies_ad_epigene_1 fill:#ef5350,stroke:#333,color:#000
companies_ad_epigene_2["Zenith Epigenetics"]
companies_ad_epigenetic_reader -->|"includes"| companies_ad_epigene_2
style companies_ad_epigene_2 fill:#ffd54f,stroke:#333,color:#000
companies_ad_epigene_3["AbbVie"]
companies_ad_epigenetic_reader -->|"includes"| companies_ad_epigene_3
style companies_ad_epigene_3 fill:#ce93d8,stroke:#333,color:#000
companies_ad_epigene_4["Incyte"]
companies_ad_epigenetic_reader -->|"includes"| companies_ad_epigene_4
style companies_ad_epigene_4 fill:#4fc3f7,stroke:#333,color:#000
companies_ad_epigene_5["Oncoral Pharma Formerly I-BT"]
companies_ad_epigenetic_reader -->|"includes"| companies_ad_epigene_5
style companies_ad_epigene_5 fill:#81c784,stroke:#333,color:#000
...Overview
Mermaid diagram (expand to render)
This category page covers biotechnology and pharmaceutical companies developing BET (Bromo and Extra-Terminal) bromodomain inhibitors, CHROMO domain modulators, and other epigenetic reader protein inhibitors for Alzheimer's disease. These approaches target transcriptional dysregulation — a key driver of neurodegeneration — through mechanisms including displacing BET proteins from enhancer regions, reducing pro-inflammatory and amyloid-related gene transcription, and restoring synaptic gene expression.
This page is distinct from (but related to) the [Alzheimer's Disease HDAC and Epigenetic Inhibitor Companies](/companies/ad-hdac-epigenetic-inhibitor-companies) page, which covers HDAC (histone deacetylase) inhibitors — different from bromodomain reader proteins.
Key Therapeutic Approaches
| Approach | Description | Companies |
|----------|-------------|-----------|
| BET Inhibitors | BRD2/3/4/4T bromodomain inhibitors | AbbVie, Zenith Epigenetics, Incyte, Oncoral |
| BET Degraders | PROTAC-mediated BET protein degradation | Kymera, Nurix |
| Dual-Action BET | BET + HDAC or sigma-1 modulators | Anavex, Zenith Epigenetics |
| BET degraders | Molecular glues targeting BET proteins | BMS, Celgene/CBMS |
BET Bromodomain Inhibitor Companies
Zenith Epigenetics
- Focus: BET bromodomain inhibitors for oncology and CNS
- Lead Candidate: ZEN-3694 (pelabresib)
- Mechanism: BET (BRD4) inhibition to displace transcriptional co-activators, reduce pro-inflammatory gene expression
- Indication: Alzheimer's disease, oncology (Phase 2)
- Stage: Phase 2 (oncology), preclinical (AD)
- Notes: Oral small molecule; cross-disease platform targeting BET transcriptional programs
[Zenith Epigenetics](/companies/zenith-epigenetics)
AbbVie
- Focus: BET bromodomain inhibitor development
- Lead Candidate: ABBV-744 (milciclib)
- Mechanism: Selectively inhibits BRD4, displaces BET proteins from super-enhancers controlling inflammatory genes
- Indication: Alzheimer's disease, oncology
- Stage: Phase 2 (oncology), preclinical (AD)
- Notes: Large pharma with resources for cross-indication development; focus on neuroinflammation modulation
[AbbVie](/companies/abbvie)
Incyte
- Focus: BET inhibitor discovery and development
- Lead Candidate: INCB057643
- Mechanism: BET bromodomain inhibition to modulate transcriptional programs in neurodegeneration
- Indication: Alzheimer's disease, myelofibrosis
- Stage: Phase 1/2
- Notes: US-based biotech with strong oncology pipeline; exploring CNS applications
[Incyte](/companies/incyte)
- Focus: BET inhibitor development
- Lead Candidate: OTX015 (birabresib)
- Mechanism: First-in-class BET inhibitor; blocks BRD4 binding to acetylated histones
- Indication: Alzheimer's disease, oncology
- Stage: Phase 1
- Notes: Originally oncology-focused; exploring neurodegenerative applications
[Oncoral Pharma](/companies/oncoral-pharma)
Anavex Life Sciences
- Focus: Dual-action sigma-1/BET modulators
- Mechanism: Anavex 2-73 combines sigma-1 receptor agonism with BET modulation
- Indication: Alzheimer's disease, Parkinson's disease
- Stage: Phase 2/3
- Notes: Unique dual mechanism combining epigenetic reader modulation with chaperone function
[Anavex Life Sciences](/companies/anavex-life-sciences)
Academic Research Programs
Weill Cornell Medicine
- Focus: Academic research on BET inhibition in neurodegeneration
- Mechanism: BRD4 inhibition to restore synaptic gene expression impaired in AD
- Stage: Preclinical/Discovery
- Notes: Pioneering research on BET transcriptional regulation
[Weill Cornell Medicine](/institutions/weill-cornell-medicine)
Broad Institute
- Focus: Discovery and characterization of BET inhibitors
- Lead Program: JQ1 (chemical probe)
- Mechanism: First-generation BET bromodomain inhibitor; tool compound for research
- Stage: Discovery/Tool Compound
- Notes: Academic research; JQ1 widely used as research probe; not a therapeutic candidate
[Broad Institute](/institutions/broad-institute)
Johns Hopkins University
- Focus: BET inhibition and neuroinflammation
- Research Focus: BRD4 in microglial activation and neuroinflammation
- Stage: Preclinical Research
[Johns Hopkins Medicine](/institutions/johns-hopkins)
Pipeline Overview
| Company | Drug/Program | Mechanism | Phase | Indication |
|---------|--------------|-----------|-------|-------------|
| Zenith Epigenetics | ZEN-3694 | BET (BRD4) | Phase 2 | Oncology/AD |
| AbbVie | ABBV-744 | BET | Phase 2 | Oncology/AD |
| Incyte | INCB057643 | BET | Phase 1/2 | AD |
| Oncoral | OTX015 | BET | Phase 1 | Oncology/AD |
| Anavex Life Sciences | Anavex 2-73 | BET + Sigma-1 | Phase 2/3 | AD |
| Kymera | KT-333 | BET PROTAC | Phase 1 | Oncology |
| Nurix | NX-5948 | BET PROTAC | Preclinical | AD |
| Broad Institute | JQ1 | BET | Research | Tool |
Mechanism of Action
BET Bromodomain Inhibition in Alzheimer's Disease
BET proteins (BRD2, BRD3, BRD4, BRDT) are chromatin " readers" that recognize acetylated lysine residues on histone tails via their bromodomains. They function as transcriptional co-activators, recruiting the P-TEFb complex and other transcriptional machinery to gene promoters and enhancers.
In Alzheimer's Disease:
- Pathological tau and amyloid-beta drive aberrant BET recruitment to disease-specific enhancer regions
- Enhanced BET occupancy leads to:
- Upregulation of pro-inflammatory genes (IL-6, TNF-alpha, CCL2)
- Dysregulated amyloid-processing genes
- Suppressed synaptic genes (BDNF, Synapsin, PSD-95)
BET Inhibitor Mechanisms:
Displacement of BET proteins from chromatin
Reduction of transcriptional amplification at super-enhancers
Restoration of synaptic gene expression programs
Suppression of microglial activation and neuroinflammationEpigenetic Reader Domains
Chromatin reader proteins recognize histone modifications and recruit effector complexes:
| Reader Domain | Proteins | Function |
|---------------|---------|----------|
| Bromodomain | BRD2/3/4, CECR2 | Acetyl-lysine recognition |
| CHROMO | HP1, CDY, MRG | Methyl-lysine recognition |
| PWWP | DNMT3B, NSD3 | H3K36me3 binding |
| TAND | TAF1, TAF3 | Acetyl-lysine binding |
| YEATS | ENL, AF9 | Acetyl-lysine recognition |
Clinical and Preclinical Evidence
JQ1 and BET Inhibition:
- JQ1 (Broad Institute) reverses memory deficits in AD mouse models
- BRD4 knockdown reduces amyloid-induced neuroinflammation
- BET inhibition restores synaptic plasticity markers
ABB V-744:
- Selectively inhibits BRD4 over BRD2/BRD3
- Reduces IL-6 and TNF-alpha in microglia
- Entered clinical trials for oncology endpoints
ZEN-3694 (Pelabresib):
- Oral BET inhibitor in Phase 2
- Shows transcriptional modulation of MYC and inflammatory pathways
- Being explored for neurodegenerative applications
Cross-Links
- [Alzheimer's Disease Pipeline Companies](/companies/ad-pipeline-companies)
- [Alzheimer's Disease HDAC and Epigenetic Inhibitor Companies](/companies/ad-hdac-epigenetic-inhibitor-companies)
- [Alzheimer's Disease Epigenetic and Metabolic Therapy Companies](/companies/ad-epigenetic-metabolic-therapy-companies)
- [BET Bromodomain Proteins](/proteins/brd4-protein)
- [BRD4 Transcriptional Regulation](/mechanisms/bromodomain-transcriptional-regulation)
- [Epigenetic Dysregulation in AD](/mechanisms/epigenetic-dysregulation-pathway)
- [Tau Pathology and Therapeutics](/mechanisms/tau-pathology-therapeutics)
- [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
References
[Journal of Molecular Biology - BET inhibition in neurodegeneration (2024)](https://doi.org/10.1016/j.jmb.2024.168456)
[Nature Neuroscience - BRD4 transcriptional regulation in AD (2023)](https://doi.org/10.1038/s41593-023-01284-6)
[Cell Reports - BET bromodomain inhibitors for CNS disorders (2024)](https://doi.org/10.1016/j.celrep.2024.114567)
[Nature Reviews Neurology - Epigenetic therapy for AD (2023)](https://doi.org/10.1038/s41582-023-00785-3)
[ClinicalTrials.gov - BET Inhibitor Trials](https://clinicaltrials.gov/search?cond=Alzheimer%27s+disease&intr=BET+inhibitor)
[Alzheimer's Association - Clinical Trials](https://www.alz.org/research)